ArticleJournal, genetic engineering & biotechnology2025
PABPC1 expression in papillary renal cell carcinoma and its significance for survival outcomes.
Article in Journal, genetic engineering & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PABPC1 in Cancer: From a Translational Housekeeper to a Stress-Responsive Regulatory Hub.Cancer science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study examines the expression pattern and prognostic relevance of PABPC1 in papillary renal cell carcinoma (pRCC) to evaluate its potential as a clinical outcome biomarker.
methodsIn papillary renal cell carcinoma (pRCC), mRNA expression levels of PABPC1 were analyzed by comparing tumor (n = 290)and normal tissues (n = 32)using the GSCALite and UALCAN databases. Immune checkpoint expression in KIRP was evaluated with TCGA transcriptomic data.Survival analyses via GSCALite assessed the relationship between PABPC1 expression levels(144 high,145 low) and patient outcomes.Correlations between PABPC1 and clinical/pathological stages were examined for prognostic value.Validation involved HE and IHC staining on 7 clinical samples, with quantitative assessment of PABPC1 protein expression in papillary renal cell carcinoma (pRCC) tissues.
resultsAn upsurge in PABPC1 was detected in papillary renal cell carcinoma (pRCC) during the study.ThereisasignificantassociationbetweenhighPABPC1 expression in patients and reduced overall survival (OS), progression-free survival (PFS), disease-specific survival (DSS), and disease-free interval (DFI) compared to lowexpression,with Log-rank P-values of 4.1e-05, 3.2e-06, 2.4e-07, and 0.00027, respectively, suggesting a poorer prognosis for KIRP patients.Moreover, the mRNA expression level of PABPC1 gradually increased with the progression of clinical and pathological stages.PD1/PDL1 inhibitors could enhance the prognosis of papillary renal cell carcinoma.
conclusionsPABPC1 could serve as a potential prognostic biomarker for individuals with KIRP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.